Nasdaq · CIK 0001335105
NMAD LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Insider trading from SEC Form 4. Last filing Jul 2, 2026.
In brief
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (NMAD) has 34 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at LIXTE BIOTECHNOLOGY HOLDINGS, INC., scored.
Transactions
Every row filed, 44 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Michael Andrew Holloway director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 40,000 | Jul 2, 2026 |
| Jul 1, 2026 | Lourdes Felix director | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 55,000 | Jul 2, 2026 |
| Jul 1, 2026 | Peter Stazzone Chief Financial Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 100,000 | Jul 2, 2026 |
| Jul 1, 2026 | Jason David Sawyer director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 65,000 | Jul 2, 2026 |
| Jul 1, 2026 | Guy Warren Primus director | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 40,000 | Jul 2, 2026 |
| Jul 1, 2026 | Geordan Garrett Pursglove CEO and Chairman of the Board | AGrant or award Common Stock | +350,000 | $0.00 | $0 | 700,000 | Jul 2, 2026 |
| May 29, 2026 | Stuart D Porter director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 25,000 | Jun 1, 2026 |
| Apr 15, 2026 | Geordan Garrett Pursglove CEO and Chairman of the Board | AGrant or award Common Stock | +350,000 | - | - | 350,000 | Apr 17, 2026 |
| Apr 15, 2026 | Peter Stazzone Chief Financial Officer | AGrant or award Common Stock | +50,000 | - | - | 50,000 | Apr 17, 2026 |
| Apr 15, 2026 | Jason David Sawyer director | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Apr 17, 2026 |
| Apr 15, 2026 | Guy Warren Primus director | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Apr 17, 2026 |
| Apr 15, 2026 | Michael Andrew Holloway director | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Apr 17, 2026 |
| Apr 15, 2026 | Lourdes Felix director | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Apr 17, 2026 |
| Apr 15, 2026 | Michael Andrew Holloway director | DDisposition to issuer Options to Purchase Common Stockderivative | -25,000 | - | - | 0 | Apr 17, 2026 |
| Apr 15, 2026 | Guy Warren Primus director | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 17, 2026 |
| Apr 15, 2026 | Geordan Garrett Pursglove CEO and Chairman of the Board | DDisposition to issuer Options to Purchase Common Stockderivative | -350,000 | - | - | 0 | Apr 17, 2026 |
| Apr 15, 2026 | Lourdes Felix director | DDisposition to issuer Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Apr 17, 2026 |
| Apr 15, 2026 | Jason David Sawyer director | DDisposition to issuer Options to Purchase Common Stockderivative | -25,000 | - | - | 0 | Apr 17, 2026 |
| Apr 15, 2026 | Peter Stazzone Chief Financial Officer | DDisposition to issuer Options to Purchase Common Stockderivative | -50,000 | - | - | 0 | Apr 17, 2026 |
| Dec 24, 2025 | Lourdes Felix director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 29, 2025 |
| Dec 24, 2025 | Guy Warren Primus director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 29, 2025 |
| Sep 1, 2025 | Peter Stazzone Chief Financial Officer | AGrant or award Options to Purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Sep 4, 2025 |
| Aug 15, 2025 | Michael Andrew Holloway director | AGrant or award Options to Purchase Common Stockderivative | +25,000 | $0.00 | $0 | 25,000 | Aug 18, 2025 |
| Aug 15, 2025 | Jason David Sawyer director | AGrant or award Options to Purchase Common Stockderivative | +25,000 | $0.00 | $0 | 25,000 | Aug 18, 2025 |
| Jul 3, 2025 | Geordan Garrett Pursglove CEO and Chairman of the Board | AGrant or award Options to Purchase Common Stockderivative | +350,000 | $0.00 | $0 | 350,000 | Jul 9, 2025 |
| Jun 30, 2025 | Yun Yen director | AGrant or award Options to Purchase Common Stockderivative | +10,000 | $0.00 | $0 | 10,000 | Jul 9, 2025 |
| Jun 30, 2025 | Yun Yen director | AGrant or award Options to Purchase Common Stockderivative | +11,632 | $0.00 | $0 | 11,632 | Jul 9, 2025 |
| Jun 30, 2025 | Rene Bernards director | AGrant or award Options to Purchase Common Stockderivative | +10,000 | $0.00 | $0 | 10,000 | Jul 8, 2025 |
| Jun 30, 2025 | Regina Brown director | AGrant or award Options to Purchase Common Stockderivative | +10,000 | $0.00 | $0 | 10,000 | Jul 8, 2025 |
| Jun 30, 2025 | Stephen J. Forman director | AGrant or award Options to Purchase Common Stockderivative | +10,000 | $0.00 | $0 | 10,000 | Jul 8, 2025 |
| Jun 30, 2025 | Rene Bernards director | AGrant or award Options to Purchase Common Stockderivative | +10,662 | $0.00 | $0 | 10,662 | Jul 8, 2025 |
| Jun 30, 2025 | Regina Brown director | AGrant or award Options to Purchase Common Stockderivative | +12,600 | $0.00 | $0 | 12,600 | Jul 8, 2025 |
| Jun 30, 2025 | Stephen J. Forman director | AGrant or award Options to Purchase Common Stockderivative | +7,754 | $0.00 | $0 | 7,754 | Jul 8, 2025 |
| Mar 31, 2025 | Rene Bernards director | AGrant or award Options to Purchase Common Stockderivative | +8,045 | $0.00 | $0 | 8,045 | Apr 2, 2025 |
| Mar 31, 2025 | Yun Yen director | AGrant or award Options to Purchase Common Stockderivative | +8,777 | $0.00 | $0 | 8,777 | Apr 2, 2025 |
| Mar 31, 2025 | Stephen J. Forman director | AGrant or award Options to Purchase Common Stockderivative | +5,851 | $0.00 | $0 | 5,851 | Apr 2, 2025 |
| Mar 31, 2025 | Regina Brown director | AGrant or award Options to Purchase Common Stockderivative | +9,508 | $0.00 | $0 | 9,508 | Apr 2, 2025 |
| Jan 20, 2025 | Rene Bernards director | AGrant or award Options to Purchase Common Stockderivative | +4,166 | $0.00 | $0 | 4,166 | Jan 22, 2025 |
| Jan 20, 2025 | Regina Brown director | AGrant or award Options to Purchase Common Stockderivative | +4,924 | $0.00 | $0 | 4,924 | Jan 22, 2025 |
| Jan 20, 2025 | Stephen J. Forman director | AGrant or award Options to Purchase Common Stockderivative | +3,030 | $0.00 | $0 | 3,030 | Jan 22, 2025 |
| Sep 30, 2024 | Rene Bernards director | AGrant or award Options to Purchase Common Stockderivative | +5,304 | $0.00 | $0 | 5,304 | Oct 29, 2024 |
| Sep 30, 2024 | Regina Brown director | AGrant or award Options to Purchase Common Stockderivative | +6,269 | $0.00 | $0 | 6,269 | Oct 29, 2024 |
| Sep 30, 2024 | Stephen J. Forman director | AGrant or award Options to Purchase Common Stockderivative | +3,858 | $0.00 | $0 | 3,858 | Oct 29, 2024 |
| Sep 30, 2024 | Yun Yen director | AGrant or award Options to Purchase Common Stockderivative | +5,786 | $0.00 | $0 | 5,786 | Oct 29, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Rene Bernardsdirector
- Regina Browndirector
- Lourdes Felixceo, cfo, officer, director
- Stephen J. Formandirector
- Michael Andrew Hollowaydirector
- Stuart D Porterdirector, owner
- Guy Warren Primusdirector
- Geordan Garrett PursgloveCEO and Chairman of the Board
- Jason David Sawyerceo, officer, director
- Peter StazzoneChief Financial Officer
- Yun Yendirector
Questions about NMAD
Answered from the filings on this page, as of the latest one.
Are insiders buying NMAD?
No. In the last 90 days no insider at LIXTE BIOTECHNOLOGY HOLDINGS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NMAD on the open market?
No open-market trade has been scored at LIXTE BIOTECHNOLOGY HOLDINGS, INC.. The latest Form 4 on file was filed on Jul 2, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
11 people have filed a Form 4 at LIXTE BIOTECHNOLOGY HOLDINGS, INC., among them Rene Bernards (director), Regina Brown (director), Lourdes Felix (CEO, CFO and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.